Novel Soft Tissue Sarcoma Treatment Receives FDA Fast Track Designation

The FDA has granted fast track designation to SOT106, an investigational antibody-drug conjugate (ADC), for the treatment of soft tissue sarcoma (STS), according to a news release from SOTIO Biotech.¹ SOT106 targets LRRC15, which the company describes as a clinically validated target that is broadly expressed across multiple prevalent sarcoma subtypes, positioning the agent to potentially reach a wide population of patients who currently have limited treatment options.

“STS remain a major unmet medical need, where decades of therapeutic progress have yet to translate into meaningful improvements for patients with advanced or recurrent disease,” Vivi Boura, MD, chief medical officer of SOTIO, said in the release.¹ “Receiving fast track designation for SOT106 is an important regulatory milestone that reinforces this program’s potential to improve outcomes for patients [with] these difficult-to-treat cancers. As we advance SOT106 toward the clinic, we aim to translate its differentiated design and LRRC15-targeting strategy into a novel therapeutic approach with the potential to offer a new treatment option for patients across multiple STS subtypes.”¹

What does fast track designation mean for SOT106?

Fast track designation is one of the FDA’s expedited program designations, intended to facilitate development and expedite review of drugs that treat serious or life-threatening conditions and address an unmet medical need.² According to the FDA, the designation allows for more frequent meetings and written communication with the agency about a drug’s development plan, and it may make a product eligible for rolling review of a marketing application, in which sections are submitted and reviewed as they are completed rather than waiting for the full application, as well as priority review if relevant criteria are met at the time of submission.^1,2

STS makes up a rare and heterogeneous group of cancers arising from mesenchymal tissue, including muscle, fat, and connective tissue, encompassing more than 60 histologic subtypes.³ The American Cancer Society estimated that approximately 13,910 new cases of STS will be diagnosed in the US in 2025, with an estimated 5400 deaths.³ Outcomes for advanced or metastatic disease remain poor; standard chemotherapy approaches have historically produced a median overall survival of approximately 12 to 18 months, underscoring the rationale behind SOTIO’s late-stage regulatory push for new mechanisms in this space.⁴

What is SOT106’s regulatory history?

Beyond the new fast track designation, SOT106 previously received orphan drug designation from the FDA for the treatment of osteosarcoma in May 2026, and the company said it expects to initiate a first-in-human clinical trial later this year, which would mark the next milestone in the drug’s clinical development.¹

SOT106 is 1 of 2 lead ADC programs at SOTIO. The other, SOT109, targets CDH17 for the treatment of colorectal cancer and received its own FDA fast track designation in July 2026.¹ The company’s broader pipeline also includes SOT201, a PD-1–targeting immunocytokine currently being evaluated in the phase 1 VICTORIA-01 study (NCT06163391) among patients with solid tumors.¹

With no first-in-human data yet reported for SOT106, efficacy and safety in patients remain unknown, and the fast track designation itself does not change the drug’s regulatory status or guarantee eventual approval. The designation does, however, formalize a closer working relationship between SOTIO and the FDA as the company moves the ADC into the clinic, a step that will generate the initial human safety and activity data needed to gauge whether SOT106’s preclinical rationale translates into clinical benefit for patients with STS.

References

1. FDA grants fast track designation to SOTIO’s SOT106 ADC for soft tissue sarcoma treatment, accelerating clinical development. News release. SOTIO Biotech. August 26, 2026. Accessed August 27, 2026. https://tinyurl.com/9rrra2x8

2. Fast Track. US Food and Drug Administration. Updated August 13, 2024. Accessed August 27, 2026. https://tinyurl.com/2s45uuev

3. Cancer facts & figures 2026. Accessed August 27, 2026. https://tinyurl.com/hmech8zr

4. Ben-Ami E, Perret R, Huang Y, et al. LRRC15 targeting in soft-tissue sarcomas: biological and clinical implications. Cancers (Basel). 2020;12(3):757. doi:10.3390/cancers12030757